University Health Network, Toronto psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University Health Network, Toronto is listed with 11 registered studies counted here, in Toronto, Canada. By compound: 6 psilocybin, 1 LSD and 5 ketamine. By registry status: 2 recruiting, 1 not yet recruiting, 1 enrolling by invitation, 4 active, not recruiting and 3 completed. By phase: 1 phase 1, 9 phase 2 and 1 not applicable. Reported start years run from 2018 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 11 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 6 |
| LSD | 1 |
| Ketamine | 5 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 18% |
| Not yet recruiting | 1 | 9% |
| Enrolling by invitation | 1 | 9% |
| Active, not recruiting | 4 | 36% |
| Completed | 3 | 27% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 1 | 9% |
| Phase 2 | 9 | 82% |
| Not applicable | 1 | 9% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | NCT07820033 | Not yet recruiting | Phase 2 | 2026-09-14 | Psilocybin |
| Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | NCT07737990 | Enrolling by invitation | Not applicable | 2026-07-01 | Psilocybin |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | Ketamine |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer | NCT07048743 | Recruiting | Phase 2 | 2025-07-02 | Psilocybin |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | NCT06506019 | Active, not recruiting | Phase 1 | 2024-10-09 | Psilocybin, LSD |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | NCT06416085 | Active, not recruiting | Phase 2 | 2024-06-06 | Psilocybin |
| Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin | NCT06341426 | Active, not recruiting | Phase 2 | 2024-02-05 | Psilocybin |
| i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | NCT06480500 | Active, not recruiting | Phase 2 | 2024-01-02 | Ketamine |
| Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression | NCT05339074 | Completed | Phase 2 | 2022-08-11 | Ketamine |
| Ketamine for Treatment-Resistant Bipolar Disorder | NCT05004896 | Completed | Phase 2 | 2022-07-04 | Ketamine |
| Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care | NCT03410446 | Completed | Phase 2 | 2018-07-16 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | LSD | Ketamine